Crovalimab

Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0) . Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His) . Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP) . Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research[1][2].

Product Specifications

CAS Number

[1917321-26-6]

Product Name Alternative

SKY59; RO7112689; RG-6107

UNSPSC

12352203

Target

Complement System

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/crovalimab.html

Purity

99.95

Solubility

10 mM in DMSO

Smiles

[Crovalimab]

Molecular Weight

(145.28 kDa)

References & Citations

[1]Taku Fukuzawa, et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017 Apr 24;7 (1) :1080.|[2]Wioleta M Zelek, et al. Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology. 2018 Nov;155 (3) :396-403.